Compare Merck & Co., Inc. (MRK) vs Omnicom Group Inc. (OMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Omnicom Group Inc. — how do they compare? Merck & Co., Inc. trades at $142.44 (market cap $351.28B), while Omnicom Group Inc. trades at $76.35 (market cap $20.97B). The key difference: Merck & Co., Inc. is far larger — about 16.8× Omnicom Group Inc.'s market cap, and Omnicom Group Inc. pays the higher dividend (4.19%). Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and Omnicom Group Inc. for 63 Days on average.
| MRK | OMC | |
|---|---|---|
Market Cap | $351.28B | $20.97B |
Volume | 7,969,665 | 2,092,899 |
Sector | Health | Media |
52-Week High | $156.43 | $88.94 |
52-Week Low | $82.49 | $67.27 |
Typical Hold Time | 98 Days | 63 Days |
Enterprise Value | $398.04B | $29.05B |
Dividend Yield | 2.39% | 4.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $142.79, up 0.61% on the day, with a bearish technical signal despite beating earnings estimates in recent quarters. The company reported 2025 revenue of $65.01B and net income of $18.25B, with a high P/E ratio of 113.9 reflecting premium valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while institutional investors have been increasing stakes.
The outlook is mixed: strong analyst consensus (68% buy ratings) and a $158.78 price target suggest upside, but high valuation and bearish technicals pose near-term risks. Key opportunities include pipeline expansion via M&A; risks involve integration challenges and patent pressures.
Omnicom Group (OMC) trades at $74.87, down 0.31% on the day, with a bearish technical signal and mixed earnings performance. The company reported strong revenue growth to $17.27B in 2025 but posted a net loss of -$54.50M due to elevated expenses. Recent news highlights leadership in digital marketing and $3.3B in new H1 2026 billings. Valuation metrics show a high P/E of 202.35 but attractive P/S of 0.84, while analyst consensus is mixed with a $104.67 price target.
OMC presents a value opportunity with its low P/S ratio and 4.2% dividend yield, offset by profitability concerns and high debt. The stock's 39% discount to consensus target suggests upside if margin improvements materialize from recent acquisitions. Key risks include advertising market volatility and integration challenges from the Interpublic deal. Institutional activity shows mixed positioning with recent trimming by major banks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Omnicom Group Inc.
Omnicom is the world's second- largest ad holding company, based on annual revenue. The firm's services, which include traditional and digital advertising and public relations, are provided worldwide, with over 85% of its revenue coming from more developed regions such as North America and Europe.
Read more on OMC →
